Understanding Antibiotics

by Pharmily · 07 Apr 2026

A Complete Guide to Antibiotic Classification by Mechanism of Action

Microbiology & Pharmacology Reference | For Clinicians, Students & Curious Minds

Introduction: Why Classify Antibiotics?

Antibiotics are medicines that kill or inhibit the growth of bacteria. With over 100 antibiotic drugs in clinical use, it can seem overwhelming to learn them all.

The key to mastering antibiotics is understanding how they work, their mechanism of action, because drugs with the same mechanism behave similarly, have similar side effects, and are often used for the same types of infections.

There are three major targets that antibiotics attack: the bacterial cell wall, the bacterial cell membrane, and the machinery bacteria use to copy their DNA or make proteins. Every antibiotic you will ever encounter fits into one of these categories.

The WHO Global Action Plan on Antimicrobial Resistance (2015) identifies rational antibiotic use as a priority. Every antibiotic prescription should be guided by the suspected pathogen, local resistance patterns, and the drug's mechanism and spectrum.

 

 

PART 1: Cell Wall Synthesis Inhibitors

Bacteria have a rigid outer wall made of peptidoglycan. Without this wall, the bacterium swells and bursts. Antibiotics in this group prevent the bacterium from building or repairing this wall. Human cells have no cell wall, which is why these drugs are generally very safe.

Beta-Lactam Antibiotics

Beta-lactams are the most widely used antibiotics in medicine. They all share a chemical 'beta-lactam ring' that blocks the enzymes bacteria use to build their cell wall. Resistance typically occurs when bacteria produce enzymes called beta-lactamases that break this ring.

Penicillins

The original beta-lactams, discovered by Alexander Fleming in 1928. Still among the most important antibiotics today.

• Natural Penicillins (Penicillin G, Penicillin V), narrow spectrum; gold standard for streptococcal infections, syphilis, and rheumatic fever prophylaxis.
• Antistaphylococcal Penicillins (Methicillin, Nafcillin, Oxacillin, Cloxacillin, Dicloxacillin, Flucloxacillin), engineered to resist staphylococcal beta-lactamase. Used for MSSA (methicillin-sensitive Staph aureus).
• Aminopenicillins (Ampicillin, Amoxicillin), broader spectrum; cover streptococci, enterococci, Listeria, and some Gram-negatives. Amoxicillin is one of the most prescribed antibiotics globally.
• Broad Spectrum Penicillins (Ampicillin/Sulbactam, Co-Amoxiclav), combined with a beta-lactamase inhibitor to overcome resistance. Amoxicillin/Clavulanate (Co-Amoxiclav) is widely used for respiratory, skin, and urinary infections.
• Anti-Pseudomonal Penicillins, Piperacillin/Tazobactam (Pip/Tazo) is the key agent here; covers Pseudomonas aeruginosa and is a workhorse of hospital medicine for serious infections.

Cephalosporins

Related to penicillins but more stable to many beta-lactamases. Organised into 5 'generations', each successive generation generally has greater Gram-negative coverage and less Gram-positive activity.

• 1st Generation (Cefazolin, Cephalexin, Cefadroxil), excellent Gram-positive cover; used for skin/soft tissue infections and surgical prophylaxis. Cefazolin is a very commonly used IV antibiotic in hospitals.
• 2nd Generation (Cefuroxime, Cefaclor, Cefoxitin), improved Gram-negative activity; used for respiratory tract infections.
• 3rd Generation (Ceftriaxone, Cefotaxime, Ceftazidime, Cefixime), strong Gram-negative cover; penetrates the CNS (useful in meningitis). Ceftriaxone is one of the most widely used IV antibiotics worldwide.
• 4th Generation (Cefepime), covers both Gram-positives and Gram-negatives including Pseudomonas; used in serious hospital infections.
• 5th Generation (Ceftaroline, Ceftobiprole), the newest; active against MRSA. Important for resistant infections.

Carbapenems & Monobactams

• Carbapenems (Imipenem, Meropenem, Ertapenem, Doripenem), the 'last resort' beta-lactams. Exceptionally broad spectrum, covering resistant organisms. Used only for serious infections to preserve their effectiveness.
• Monobactams (Aztreonam), active only against Gram-negative bacteria including Pseudomonas; safe in penicillin allergy as it has a different ring structure.

Non-Beta-Lactam Cell Wall Agents

• Glycopeptides (Vancomycin, Teicoplanin, Telavancin, Dalbavancin, Oritavancin), block cell wall synthesis differently from beta-lactams; used for MRSA and serious Gram-positive infections. Vancomycin requires monitoring of blood levels.
• Others: Fosfomycin, used for UTI and as a reserve agent. Bacitracin, topical use for skin infections. Cycloserine, used in drug-resistant TB regimens.

 

 

PART 2: Cell Membrane Disruptors

Rather than attacking the cell wall, these antibiotics directly damage the bacterial cell membrane, causing the contents to leak out and killing the bacterium rapidly.

• Colistin (Polymyxin E), a 'last resort' antibiotic for carbapenem-resistant Gram-negative bacteria (e.g., KPC, NDM producing organisms). Nephrotoxic; use with close monitoring.
• Daptomycin, cyclic lipopeptide; excellent for MRSA bacteraemia and endocarditis. Important caveat: inactivated by lung surfactant, so do NOT use for pneumonia.

PART 3: Protein Synthesis Inhibitors

Bacteria make proteins on structures called ribosomes. Bacterial ribosomes differ from human ribosomes in structure, allowing antibiotics to selectively block bacterial protein production without harming human cells.

30S Ribosomal Subunit Inhibitors

• Tetracyclines (Tetracycline, Doxycycline, Oxytetracycline, Minocycline), broad-spectrum; excellent for atypical organisms, Chlamydia, Rickettsia, malaria prophylaxis. Avoid in pregnancy and children under 8 (affects developing teeth and bones). Doxycycline is one of the most versatile antibiotics in clinical practice.
• Glycylcyclines (Tigecycline), a modified tetracycline; covers MDR organisms including MRSA. Reserved for serious resistant infections.
• Aminoglycosides (Gentamicin, Amikacin, Tobramycin, Streptomycin, Neomycin), bactericidal; used for serious Gram-negative and TB infections. Significant nephrotoxicity and ototoxicity, require monitoring of drug levels and renal function.

50S Ribosomal Subunit Inhibitors

• Macrolides (Erythromycin, Clarithromycin, Azithromycin, Spiramycin), cover atypical organisms; used in respiratory infections and as alternatives in penicillin allergy. Azithromycin is widely used for its once-daily dosing and good tissue penetration.
• Ketolides (Telithromycin), modified macrolide for resistant respiratory pathogens; limited by hepatotoxicity.
• Chloramphenicol, broad-spectrum; reserved for meningitis and typhoid in settings without alternatives due to rare but serious aplastic anaemia risk.
• Oxazolidinones (Linezolid, Tedizolid), for MRSA, VRE, drug-resistant TB. Linezolid interacts with certain antidepressants (serotonin syndrome risk); monitor full blood count (thrombocytopenia).
• Lincosamides (Clindamycin), excellent for anaerobic infections, skin/soft tissue, and bone infections. Risk of Clostridioides difficile colitis.
• Streptogramins (Quinupristin/Dalfopristin), for VRE and MRSA when other options fail.
• Others: Fusidic Acid, primarily for MRSA skin infections (topical and oral). Rifaximin, non-absorbed gut antibiotic for traveller's diarrhoea and hepatic encephalopathy.

 

 

PART 4: Nucleic Acid Synthesis Inhibitors

These antibiotics interfere with DNA replication or the production of building blocks needed for DNA, killing bacteria by preventing reproduction.

Fluoroquinolones

Fluoroquinolones inhibit bacterial enzymes (DNA gyrase and topoisomerase IV) needed for DNA replication. They are broad-spectrum and well-absorbed orally, making them valuable in both community and hospital settings.

• 2nd Generation (Ciprofloxacin, Norfloxacin, Ofloxacin), excellent Gram-negative coverage; Ciprofloxacin is the workhorse for UTI, GI infections, and typhoid (where sensitive). Norfloxacin is restricted to UTI.
• 3rd Generation (Levofloxacin, Sparfloxacin), respiratory fluoroquinolones; added Gram-positive and atypical coverage, making them ideal for CAP.
• 4th Generation (Moxifloxacin, Gatifloxacin, Trovafloxacin), broadest spectrum including anaerobes. Moxifloxacin is now part of the new TB regimen (2HPZM). Gatifloxacin linked to dysglycaemia.

Important: Fluoroquinolones can prolong QT interval; avoid in patients with cardiac arrhythmias. Avoid in children and pregnancy (cartilage effects). Rising resistance is a growing concern.

Antifolates

These drugs block the folate synthesis pathway that bacteria need to make DNA building blocks. Human cells obtain folate from diet and do not synthesise it, making this a selective target.

• Sulfonamides (Sulfamethoxazole, Sulfadiazine, Sulfadoxine), block an early step in folate synthesis (DHPS inhibition). Largely replaced by combination products but still used in toxoplasmosis (Sulfadiazine) and malaria (Sulfadoxine/Pyrimethamine).
• DHFR Inhibitors (Trimethoprim), block a later step in folate synthesis. Used alone for UTI, but most effective in combination with Sulfamethoxazole.
• Combination (Co-Trimoxazole = Trimethoprim + Sulfamethoxazole), double blockade of folate synthesis; highly effective. Used for UTI, Pneumocystis jirovecii pneumonia (PCP) prophylaxis and treatment in HIV, and Nocardia. One of the most important drugs in HIV care.

 

 

Why This Matters: Antibiotic Stewardship

Understanding antibiotic classes is not just academic, it has real-world life-saving implications. Antibiotic resistance occurs when bacteria evolve mechanisms to survive the drugs we use against them. Resistance spreads when antibiotics are overused, misused, or taken incorrectly.

• Use the narrowest-spectrum antibiotic that treats the infection. Broad-spectrum antibiotics kill normal flora and drive resistance.
• Always complete the prescribed course, even if you feel better early.
• Never share antibiotics or use leftover antibiotics from previous illness.
• Antibiotics do not treat viral infections (colds, flu, COVID-19). Taking them for viral illness has no benefit and causes harm.

 

ESKAPE Pathogens — Clinical Relevance

The ESKAPE pathogens (Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacter species) account for the majority of hospital-acquired infections and represent the greatest antibiotic resistance threats globally (Kumar et al.)

 

Frequently Asked Questions (FAQs)

Q1: What is the difference between bactericidal and bacteriostatic antibiotics?

Bactericidal antibiotics kill bacteria directly (e.g., beta-lactams, aminoglycosides, fluoroquinolones). Bacteriostatic antibiotics inhibit bacterial growth and reproduction, relying on the host immune system to eliminate the bacteria (e.g., tetracyclines, macrolides, chloramphenicol). In immunocompromised patients, bactericidal agents are generally preferred.

Q2: Why do some antibiotics only work on Gram-positive or Gram-negative bacteria?

The distinction lies in bacterial cell wall structure. Gram-positive bacteria have a thick peptidoglycan layer with no outer membrane. Gram-negative bacteria have a thin peptidoglycan layer but are protected by an outer lipopolysaccharide membrane that excludes large molecules. Vancomycin, for example, cannot penetrate the Gram-negative outer membrane and is therefore inactive against these organisms.

Q3: What is antibiotic resistance and why does it develop?

Antibiotic resistance occurs when bacteria develop mechanisms to withstand the effects of antibiotics. These mechanisms include producing enzymes that destroy antibiotics (beta-lactamases), modifying their target sites (altered PBPs in MRSA), pumping antibiotics out of the cell (efflux pumps), or reducing membrane permeability.

Resistance develops and spreads through natural selection — bacteria exposed to antibiotics that survive pass on resistance genes to subsequent generations and to other bacteria via horizontal gene transfer.

Q4: Why are broad-spectrum antibiotics not always better than narrow-spectrum ones?

Broad-spectrum antibiotics cover many bacterial species but also kill beneficial normal flora, disrupting the microbiome and increasing the risk of opportunistic infections like Clostridioides difficile colitis. Narrow-spectrum antibiotics target specific pathogens with less collateral damage. Once a specific pathogen is identified, de-escalating to a narrow-spectrum agent is best practice — this is antibiotic stewardship.

Q5: What is antibiotic stewardship?

Antibiotic stewardship refers to coordinated interventions to improve and measure the appropriate use of antibiotics. Key principles include: prescribing only when genuinely needed, selecting the right drug, dose, and duration, de-escalating once culture results are available, and avoiding prophylactic or empirical courses without clinical indication. The WHO identifies stewardship as essential to combating antimicrobial resistance.

 

Disclaimer: This article is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional for clinical decisions.